Overview

• The Girona-area complex spans 114,000 m², with the completed first phase delivering 28,000 m² for production, research, and corporate operations.
• New facilities include a 7,500 m² R&D building, a Business and Technology building, a BSL2+ bacterial culture unit with bioreactors up to 2,000 liters, and a cell-culture platform now being equipped.
• Hipra reports several hundred employees already on site and projects about 1,000 direct jobs at full operation, plus roughly 2,000 indirect roles.
• The microbial production platform is slated to start in January with regulatory validation expected around mid-next year, according to the company.
• Backed by an EU framework contract and participation in EU-FAB and Speedcell projects, Hipra positions the campus to bolster European vaccine readiness, building on its EMA-authorized COVID-19 vaccine, Bimervax.